233 related articles for article (PubMed ID: 26609177)
1. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
5. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
6. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement.
Apostolova I; Riethdorf S; Buchert R; Derlin T; Brenner W; Mester J; Klutmann S
Ann Nucl Med; 2010 Jul; 24(6):477-83. PubMed ID: 20449694
[TBL] [Abstract][Full Text] [Related]
7. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
8. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
12. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
13. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
14. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
15. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
17. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
19. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
20. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
